CMMB Q3 2020 Earnings — Chemomab Therapeutics Ltd. Revenue & Financial Results | Market Cap Arena

CMMBChemomab Therapeutics Ltd.

$12M

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$1M

Net Income

-$1M

EPS (Diluted)

$-5.32

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$2M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$8M

Total Liabilities

$2M

Stockholders' Equity

$5M

Cash & Equivalents

$7M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$1M	-$7M	+83.1%
Net Income	-$1M	-$7M	+82.9%